<bill session="116" type="h" number="5133" updated="2023-01-11T13:44:05Z">
  <state datetime="2019-11-21">REPORTED</state>
  <status>
    <unknown datetime="2019-11-21"/>
  </status>
  <introduced datetime="2019-11-18"/>
  <titles>
    <title type="display">Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
    <title type="official" as="introduced">To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.</title>
    <title type="short" as="reported to house">Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
    <title type="short" as="introduced">Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
  </titles>
  <sponsor bioguide_id="C001084"/>
  <cosponsors>
    <cosponsor bioguide_id="C001118" joined="2019-11-20"/>
    <cosponsor bioguide_id="C001093" joined="2019-11-18"/>
    <cosponsor bioguide_id="M001208" joined="2019-11-20"/>
    <cosponsor bioguide_id="N000002" joined="2019-11-18"/>
    <cosponsor bioguide_id="S000244" joined="2019-11-18"/>
  </cosponsors>
  <actions>
    <action datetime="2019-11-18">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-11-18" state="REFERRED">
      <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
    </action>
    <action datetime="2019-11-18">
      <text>Referred to the House Committee on the Judiciary.</text>
    </action>
    <action datetime="2019-11-19">
      <text>Subcommittee on Antitrust, Commercial, and Administrative Law Discharged.</text>
    </action>
    <action datetime="2019-11-21">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-11-21" state="REPORTED">
      <text>Ordered to be Reported.</text>
    </action>
    <action datetime="2020-12-24">
      <text>Reported by the Committee on Judiciary. H. Rept. 116-695.</text>
    </action>
    <calendar datetime="2020-12-24" calendar="Union" number="578">
      <text>Placed on the Union Calendar, Calendar No. 578.</text>
    </calendar>
  </actions>
  <committees>
    <committee code="HSJU" name="House Judiciary" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSJU05" name="House Judiciary" subcommittee="Administrative State, Regulatory Reform, and Antitrust" activity="Discharged, Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="s" number="1416" relation="unknown"/>
    <bill session="116" type="h" number="2486" relation="unknown"/>
    <bill session="116" type="h" number="4398" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Commerce"/>
    <term name="Administrative remedies"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Consumer affairs"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Intellectual property"/>
    <term name="Judicial review and appeals"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2020-12-31T17:30:58Z" status="Reported to House">Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.</summary>
  <committee-reports>
    <report>H. Rept. 116-695</report>
  </committee-reports>
</bill>
